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background
North Carolina has added nucleic acid amplification testing for the human immunode-
ficiency virus (HIV) to standard HIV antibody tests to detect persons with acute HIV in-
fection who are viremic but antibody-negative.
methods
To determine the effect of nucleic acid amplification testing on the yield and accuracy
of HIV detection in public health practice, we conducted a 12-month observational
study of methods for state-funded HIV testing. We compared the diagnostic performance
of standard HIV antibody tests (i.e., enzyme immunoassay and Western blot analysis)
with an algorithm whereby serum samples that yielded negative results on standard
antibody tests were tested again with the use of nucleic acid amplification. A surveillance
algorithm with repeated sensitive–less-sensitive enzyme immunoassay tests was also
evaluated. HIV infection was defined as a confirmed positive result on a nucleic acid am-
plification test or as HIV antibody seroconversion.
results
Between November 1, 2002, and October 31, 2003, 109,250 persons at risk for HIV in-
fection who had consented to HIV testing presented at state-funded sites. There were
606 HIV-positive results. Established infection, as identified by standard enzyme immu-
noassay or Western blot analysis, appeared in 583 participants; of these, 107 were iden-
tified, with the use of sensitive–less-sensitive enzyme immunoassay tests, as recent in-
fections. A total of 23 acutely infected persons were identified only with the use of the
nucleic acid amplification algorithm. With all detectable infections taken into account,
the sensitivity of standard antibody testing was 0.962 (95 percent confidence interval,
0.944 to 0.976). There were two false positive results on nucleic acid amplification tests.
The specificity and positive predictive value of the algorithm that included nucleic acid
amplification testing were greater than 0.999 (95 percent confidence interval, 0.999 to
>0.999) and 0.997 (95 percent confidence interval, 0.988 to >0.999), respectively. Of the
23 acute HIV infections, 16 were detected at sexually transmitted disease clinics. Emer-
gency measures for HIV prevention protected 48 sex partners and one fetus from high-
risk exposure to HIV.
conclusions
The addition of nucleic acid amplification testing to an HIV testing algorithm signifi-
cantly increases the identification of cases of infection without impairing the perfor-
mance of diagnostic testing. The detection of highly contagious, acutely infected persons
creates new opportunities for HIV surveillance and prevention.
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cute infection with the human
immunodeficiency virus (HIV) is rarely rec-
ognized. It is associated with a high prob-
ability of secondary HIV transmission,1-5 probably
because of the magnitude of viremia and genital
shedding of virus. Since routine HIV antibody tests
yield negative results during the first four to five
weeks of HIV infection,6 acute infections can be di-
agnosed during this period only with the use of
tests for viral antigens, nucleic acids, or both.
Sensitive nucleic acid amplification tests are
routinely used by blood banks to protect the blood
supply.7 However, concerns about cost and speci-
ficity have precluded the use of these tests for clini-
cal testing for HIV, except in the evaluation of sus-
pected acute retroviral syndromes.8 Results from
several small studies,9-15 including one conducted
in North Carolina,14 have suggested that acute (an-
tibody-negative) infections that can be detected by
nucleic acid amplification testing may be identified
regularly in some clinical testing settings. Most re-
cently, the use of algorithms12-15 involving the test-
ing of pooled specimens has been proposed as a
way to make nucleic acid amplification testing ac-
curate and cost effective.14
We designed a system based on the concomi-
tant use of nucleic acid amplification and antibody
testing for the identification and public health man-
agement of patients with acute HIV infection who
received voluntary counseling and testing in North
Carolina. We report the results of the first year of
this program.
study design
A 12-month observational study was conducted to
evaluate a new strategy for HIV testing in North
Carolina. The primary objective was to compare the
performance and yield of standard HIV antibody
tests with an algorithm that included both standard
antibody tests and nucleic acid amplification tests.
Additional objectives were to assess the feasibility
of timely intervention in networks of social and sex-
ual contact and to compare nucleic acid amplifica-
tion tests with sensitive–less-sensitive enzyme im-
munoassay tests with respect to estimation of the
incidence of HIV infection.16-18
study subjects
All consenting persons who presented for HIV
counseling and testing at 110 publicly funded sites
in North Carolina participated in this study between
November 1, 2002, and October 31, 2003. All test-
ing was confidential and was linked to patient in-
formation with the use of a system of unique iden-
tifiers, according to state public health statutes.
Anonymous, unlinked HIV testing is not available
in North Carolina.
study procedures
Figure 1 depicts the procedures of the North Caro-
lina Department of Health and Human Services for
HIV testing, field services (e.g., notification of test
results and partner counseling), and surveillance,
which provided the framework for this study. In-
formation about characteristics of the testing sites,
demographics, reasons for testing, HIV-testing his-
tory, and lifetime risk factors was taken from test-
ing forms and entered into a secure database. Sup-
plemental, detailed information about symptoms,
risk behavior, and partnerships was collected at
follow-up interviews from subjects with HIV tests
positive for acute infection by specialists in HIV and
sexually transmitted disease intervention. Written
informed consent for all HIV testing and for the
use of personal information in evaluation research
was obtained during pretest counseling and at ini-
tial interviews with disease-intervention specialists.
All testing and evaluation procedures were ap-
proved by institutional review boards of the state of
North Carolina and the University of North Caroli-
na School of Medicine.
Standard HIV Antibody Testing
Serum samples submitted for HIV testing were pro-
cessed centrally at the North Carolina State Labora-
tory of Public Health and maintained at ¡70° C.
Standard Vironostika HIV type 1 (HIV-1) enzyme
immunoassay (bioMérieux) and Western blot analy-
sis (Bio-Rad Laboratories) kits were used for anti-
body screening.
Sensitive–Less-Sensitive Antibody Testing
Antibodies that appear during the early stages of
HIV infection are typically associated with a low ti-
ter. Janssen et al.16 developed a detuned antibody
test (the “less sensitive” HIV antibody enzyme im-
munoassay) that continues to yield a negative result
for 170 days, on average, after a standard (“sensi-
tive”) antibody enzyme immunoassay test becomes
positive,17 thereby allowing the identification of re-
cent infections. For this study, serum samples that
had positive results on the standard antibody en-
a
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zyme immunoassay or Western blot analysis were
made anonymous (unique identifiers were recoded)
and then tested again at a laboratory certified by the
Centers for Disease Control and Prevention (CDC)
with the use of a less-sensitive HIV antibody enzyme
immunoassay test based on the Vironostika kit.17
Nucleic Acid Amplification Testing
Serum samples that were antibody-negative or
for which there was an indeterminate result were
pooled, as previously described,14 with the use of an
automated liquid-handling robot (Biomek FX, Beck-
man Coulter). The pooling algorithm allowed spec-
imens to be screened by nucleic acid amplification
in large groups, an approach that reduced testing
costs and the potential for false positive results
(which are expected to be approximately propor-
tional to the number of tests performed). Pools of
10 samples were first created by combining aliquots
from consecutive individual specimens; pools of 90
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were created by combining aliquots from 9 of these
pools of 10. The pools of 90 were then screened by
nucleic acid amplification for HIV-1 RNA with the
use of the NucliSens HIV-1 QL assay (bioMérieux),
a qualitative assay that can reliably detect concen-
trations exceeding 75 copies of HIV-1 RNA per mil-
liliter. A pool of 90 specimens, therefore, would
be likely to be positive on nucleic acid amplifica-
tion testing if the pool included at least 1 specimen
with more than 6750 copies of HIV-1 RNA per mil-
liliter. Nucleic acid amplification can occasionally
detect even lower concentrations, depending on
the efficiency of nucleic acid amplification in a test-
ing run.19
Only pools of 90 specimens that were positive
on nucleic acid amplification tests were broken
down for further testing by this method — first by
the examination of pools of 10 and finally by tests
of individual specimens. Individual specimens that
were positive on nucleic acid amplification under-
went repeated enzyme immunoassay testing and
quantitative HIV-1 RNA testing (Roche Amplicor
1.5, Roche Molecular Systems; lower detection
limit, 500 copies per milliliter). Confirmatory se-
rum samples obtained subsequently from subjects
with possible acute HIV infection and their recent
sexual contacts were tested individually for HIV an-
tibodies and, if the results were negative, by nucleic
acid amplification.
Field Protocols
North Carolina public health statutes mandate that
the following functions be fulfilled by specialists in
HIV and sexually transmitted disease intervention
for all newly identified HIV-positive persons: name-
based reporting, notification of HIV-positive per-
sons of their test results, provision of risk-reduction
counseling, and provision of partner counseling
and referral services (Fig. 1). Cases of possible
acute HIV infection, as determined by a positive re-
sult on a nucleic acid amplification test, and cases
of documented seroconversion found during the
routine evaluation of HIV reports were assigned to
a team of 12 specifically trained disease-interven-
tion specialists, who performed initial interviews,
confirmatory tests, and referrals to care within 72
hours after receiving a report. For persons with pos-
sible acute HIV infection, initial counseling focused
on the indeterminate nature of HIV test results and
the urgent need for additional evaluation and con-
firmatory testing; repeated testing was recommend-
ed at 2 weeks (and, if necessary, at 4 and 12 weeks).
Sexual partners or those who had shared needles
and hence had possibly been exposed to acute HIV
infection within eight weeks before the initial in-
terview were rapidly notified and offered testing.
Partners who were exposed outside the eight-week
window were notified only after confirmation of
seroconversion in the index case.
analyses
The population at risk for HIV infection was de-
fined as the population of persons who did not re-
port a previous positive HIV test. HIV infection was
defined as a positive result on enzyme immunoas-
say and Western blot analysis at either the initial or
follow-up test or as a positive result on nucleic acid
amplification at both the initial and follow-up tests
(Fig. 1). Persons for whom the HIV antibody status
was negative or indeterminate but positive on ini-
tial nucleic acid amplification testing were defined
as having acute HIV infection; those whose anti-
body status was positive on initial testing were de-
fined as having established HIV infection. The per-
formance of testing algorithms during screening
of the routine testing population was evaluated on
the basis of all detectable HIV infections according
to the above-mentioned reference standard. The
sensitivity of the combined algorithm and the spec-
ificity of the standard algorithm were assumed to
be 100 percent. For surveillance purposes, after
sensitive–less-sensitive enzyme immunoassay test-
ing, subjects who had positive results on a sensitive
enzyme immunoassay but negative results on a less-
sensitive enzyme immunoassay were classified as
probably having recent infection16,17; the remain-
ing subjects, with positive results on a less-sensi-
tive enzyme immunoassay, were classified as having
infection of unknown duration, as recommended
because of concerns about misclassification.20
Estimation of Incidence
Incidence rates were estimated from observational
data on acute and recent HIV infections, according
to the Serologic Testing Algorithm for Recent HIV
Seroconversion.18 In this algorithm, the number of
people in a population that are detected as having
incident infection by an assay or assays (Ninc) can
be divided by the window period in days (w) to give
the number who have incident infection per day
(Ninc/w); w was assumed to be 170 days with the
less-sensitive enzyme immunoassay17 and 28 days
with nucleic acid amplification,6 yielding a window
period of 198 days when both assays were used.
n engl j med 352;18 www.nejm.org may 5, 2005
detection of acute infections during hiv testing
1877
The annual number was determined by multiplica-
tion of the observed number of incident infections
per day by 365 (365¬Ninc/w). We divided this figure
by the number at risk for infection in the popula-
tion to obtain an estimate of the annual incidence
rate ([365¬Ninc/w]/[number at risk¬1 year]). HIV-
seronegative subjects and those with acute or re-
cent HIV infections were included in this denomi-
nator. The 95 percent confidence interval for each
estimate of incidence was calculated with the use
of a Poisson distribution.18
testing population
Between November 2002 and October 2003,
110,890 persons sought publicly funded, volun-
tary HIV counseling and testing in North Carolina.
The study population consisted of 109,250 subjects
for whom there were complete testing data and
who were classified as being at risk for HIV infec-
tion (Fig. 2). Forty-five percent of the subjects at risk
were self-identified as black, 37 percent as white,
and 15 percent as Hispanic. Most subjects under-
went HIV testing at sexually transmitted disease
clinics (41 percent); other testing sites included
prenatal–obstetrical clinics (17 percent), family-
planning clinics (16 percent), freestanding HIV test-
ing sites (11 percent), or jails (3 percent). Only 3 per-
cent of subjects identified themselves as men who
have sex with men, and 2 percent reported hetero-
sexual contact and the use of injection drugs; 33 per-
cent of the testing population self-identified as het-
erosexual, with no other risk factors.
case identification
As detailed in Table 1, 606 new HIV infections were
identified with the use of the enhanced algorithm
(prevalence, 5.5 cases per 1000 persons at risk). Of
those, 583 subjects had antibody-positive estab-
lished infection (prevalence, 5.3 per 1000). On the
basis of the results of sensitive–less-sensitive en-
zyme immunoassay tests suggesting low antibody
titer, the surveillance algorithm defined 107 of the
antibody-positive persons as probably having re-
cent infection (prevalence, 1.0 per 1000).16,17 An ad-
ditional 23 persons were antibody-negative and had
positive nucleic acid amplification test results and
thus met the study definition of acute HIV infection
(prevalence, 0.2 per 1000).
Overall, the use of nucleic acid amplification
tests increased the rate of HIV case identification
by 3.9 percent over that with standard antibody test-
ing. Differences in the frequency of acute HIV infec-
tion were significant (P<0.001) across all types of
confidential HIV testing sites, as illustrated in Fig-
ure 3. Most of the persons with acute infections
(16 of 23, or 70 percent) were identified at sexually
transmitted disease clinics. The remainder of the
acute infections were detected at freestanding HIV
testing sites and at jails.
results
Figure 2. Flow Chart of the Study Population.
The study samples are indicated in the shaded areas.
110,890 Persons requested vol-
untary counseling and testing
109,250 Successfully tested;
constituted population at risk
108,667 Had negative or
indeterminate results on enzyme
immunoassay or Western blot
tests; RNA screened
1427 Had insufficient data
213 Were previously HIV-positive
583 Had enzyme immunoassay
and Western blot tests showing
established HIV infection
107 Had less-sensitive enzyme
immunoassay test showing
recent infection
108,642 Had negative results on
RNA screening: HIV-negative
25 Were RNA-positive
23 Were confirmed to have
acute HIV infection
2 Had repeated enzyme immuno-
assay and RNA screening through
wk 12: RNA false positive; HIV-
negative
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As shown in Table 1, acute and recent HIV infec-
tions were generally more prevalent among men,
black persons, and persons older than 24 years than
among other demographic groups. There was also
a significantly increased prevalence of both acute
and recent HIV infections among men who have sex
with men and among persons tested for HIV in-
fection as a result of having another sexually trans-
mitted disease.
Signs and Symptoms of Acute Infection
No subjects were believed, on clinical grounds, to
have acute HIV infection at the time of testing, al-
though it was determined retrospectively that 7 of
the 23 subjects who met the study definition of acute
infection (30 percent) had presented with symp-
toms of acute retroviral illness.21 Symptoms de-
veloped in an additional six subjects (26 percent)
during the seroconversion period. Eight subjects
* Categories that were included contained at least 1000 subjects; data were not available for all subjects in every category. Acute denotes acute 
HIV infection as determined by a positive result on a nucleic acid amplification test, recent Ab+ the likelihood that a patient has recent HIV in-
fection as determined by a positive result on a sensitive enzyme immunoassay and a negative result on a less-sensitive enzyme immunoassay, 
all Ab+ an HIV antibody-positive result on an enzyme immunoassay and Western blot analysis, and CI confidence interval.
† Differences in the prevalence of acute infection and in the prevalence of acute or recent infection were significant (P<0.05).
‡ Differences in the prevalence of acute or recent infection were significant (P<0.05).
§ Race and ethnic background were self-reported. Differences in the prevalence of acute or recent infection were significant (P<0.05).
Table 1. Frequency and Prevalence of HIV Infections in the General Testing Population in North Carolina, According to Disease Stage 
and Demographic Characteristics and Risk Factors (November 1, 2002, through October 31, 2003).*
Variable
No. 
at Risk No. of HIV-Positive Cases Prevalence of HIV-Positive Cases
Acute Recent Ab+ All Ab+ Acute Recent Ab+ All Ab+
no./1000 (95% CI)
All subjects 109,250 23 107 583 0.2  (0.1–0.3) 1.0 (0.8–1.2) 5.3 (4.9–5.8)
Sex†
Male 36,925 15 69 378 0.4  (0.2–0.7) 1.9 (1.4–2.3) 10.2 (9.2–11.3)
Female 70,900 8 38 200 0.1  (0.05–0.2) 0.5 (0.4–0.7) 2.8 (2.4–3.2)
Age‡
>24 yr 54,534 16 74 454 0.3  (0.2–0.5) 1.4 (1.1–1.7) 8.3 (7.6–9.1)
≤24 yr 53,318 7 31 122 0.1  (0.05–0.3) 0.6 (0.4–0.8) 2.3 (1.9–2.7)
Race or ethnic background§
White 40,472 5 29 106 0.1  (0.04–0.3) 0.7 (0.5–1.0) 2.6 (2.1–3.1)
Black 48,796 16 64 410 0.3  (0.2–0.5) 1.3 (1.0–1.7) 8.4 (7.6–9.2)
Hispanic 16,627 1 14 53 0.1  (0.002–0.3) 0.8 (0.5–1.4) 3.2 (2.4–4.1)
Native American 1,137 1 0 4 0.9  (0.02–4.9) 0  (0–3.2) 3.5 (1.0–8.9)
Risk category†
Heterosexual contact 35,647 1 18 102 0.03 (0.001–0.2) 0.5 (0.3–0.8) 2.9 (2.3–3.5)
Presence of sexually transmitted
disease
21,968 7 11 72 0.3  (0.1–0.7) 0.5 (0.3–0.9) 3.3 (2.6–4.1)
Has a sex partner at risk 19,975 2 23 141 0.1  (0.01–0.4) 1.2 (0.7–1.7) 7.1 (5.9–8.3)
Does not have an acknowledged 
sex partner
12,715 0 5 20 0 (0–0.3) 0.4 (0.1–0.9) 1.6 (1.0–2.4)
Has a sex partner and uses non-
injection drugs
6,077 2 2 17 0.3  (0.04–1.2) 0.3 (0.04–1.2) 2.8 (1.6–4.5)
Man who has sex with men 3,777 7 37 170 1.9  (0.7–3.8) 9.8 (6.9–13.5) 45.0 (38.6–52.1)
Heterosexual and uses injection drugs 2,471 1 5 26 0.4  (0.01–2.3) 2.0 (0.7–4.7) 10.5 (6.9–15.4)
Victim of sexual assault 1,416 1 1 2 0.7  (0.02–3.9) 0.7 (0.02–3.9) 1.4 (0.2–5.1)
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reported symptoms related to a sexually transmit-
ted disease, and one was pregnant. The median
HIV-1 viral load on initial testing was 258,000 cop-
ies of HIV-1 RNA per milliliter, with a range of 2609
to 4,998,000 copies per milliliter.
performance of diagnostic tests
Follow-up testing demonstrated antibody sero-
conversion in 20 of 25 persons who had tested pos-
itive on nucleic acid amplification. Two persons
were again positive on nucleic acid amplification
and antibody negative on initial follow-up testing,
but they refused further testing. In one person who
was followed up for 12 months, Pneumocystis carinii
pneumonia and the acquired immunodeficiency
syndrome developed, but HIV antibodies were not
detected. Two patients had negative results on both
nucleic acid amplification and antibody testing at
follow-up and were classified as having false pos-
itive results.
The estimate of sensitivity for the standard an-
tibody-testing algorithm was 0.962 (95 percent
confidence interval, 0.944 to 0.976). The positive
predictive value of the algorithm that combined
standard antibody testing and nucleic acid ampli-
fication testing with pooling was 0.997 (95 percent
confidence interval, 0.988 to >0.999). The positive
predictive value of nucleic acid amplification with
pooling alone was 0.920 (95 percent confidence
interval, 0.740 to 0.990). The specificity of nucleic
acid amplification testing with pooling was greater
than 0.999 (95 percent confidence interval, 0.999
to >0.999).
interventions targeting acute infection
All subjects with acute infection were notified of
their infection, 17 of the 23 (74 percent) within 72
hours after the test result became available. No ad-
verse events (e.g., psychological trauma, violence
against or from partners, violation of confidentiali-
ty, or inappropriate HIV therapy) were reported dur-
ing follow-up. Twenty-one subjects with acute in-
fection successfully began specialty medical care,
and 20 of them, including 1 pregnant woman, re-
ceived antiretroviral drug therapy from their person-
al physicians. The offspring of the pregnant wom-
an was HIV-negative.
Forty-eight sexual partners of subjects with acute
Figure 3. Frequency of Newly Diagnosed HIV Infections in North Carolina, November 1, 2002, through October 31, 2003, 
According to Type of Testing Site and Stage of Disease.
All sites were publicly funded and provided confidential HIV testing. The numbers in parentheses are the population
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HIV infection received counseling for risk reduc-
tion. Eighteen of these partners (38 percent) had
HIV infection — in 13 cases (27 percent) previously
recognized and in 5 (10 percent) newly detected.
Eleven of the partners were probably the source of
the acute HIV infections. Ten of these possible trans-
mitters were aware of their HIV infection, but only
three had disclosed their status to their partners.
Three of the possible transmitters had been named
in surveillance records as a potential source of in-
fection in at least three other cases, suggesting a
possible role as “core transmitters.”22
social networks and risk associations
Disease-intervention specialists collected data on
the social networks of acutely infected subjects
through in-depth interviews. Eleven of 15 acutely in-
fected men named male sexual partners at the time
of the interview, whereas only 7 had reported on
their testing form that they had sex with men. So-
cial factors that were identified as possibly con-
tributing to the risk of transmission in the 23 in-
dex cases of acute infection included recent prison
release (5 subjects), sex work (5), multiple anony-
mous sexual partnerships (4), and heavy drug or al-
cohol use (10).
Four subjects with acute HIV infection were col-
lege students; two in one town were identified with-
in one month of each other. Surveillance records
were examined with the use of traditional outbreak-
investigation techniques for evidence of increased
rates of HIV infection among college students and
noncollege students; this review revealed a new HIV
outbreak in both student groups that had begun
across North Carolina in mid-2001 among young
black men who have sex with men.23
estimation of incidence on the basis 
of acute and recent infections
When used in conjunction with an algorithm based
on sensitive–less-sensitive enzyme immunoassays,
nucleic acid amplification testing increased the
number of incident cases available for the estima-
tion of incidence of HIV infection by 21 percent. In-
cidence rates that were calculated only on the basis
of acute HIV infections (as detected on nucleic acid
amplification tests) correlated strongly with inci-
dence rates that were calculated only on the basis
of recent HIV infections (as detected by sensitive–
less-sensitive enzyme immunoassays) across both
demographic categories (r2=0.95) and risk cate-
gories (r2=0.95) with sufficient sample size. The
inclusion of data from nucleic acid amplification
testing did not change the estimated incidence rate
by more than 5 percent in either direction for large
patient categories that included men, women, men
who have sex with men, black persons, and white
persons.
With the use of the combined data from nucle-
ic acid amplification testing and sensitive–less-
sensitive enzyme immunoassays, the overall inci-
dence in the study population was estimated at 2.2
HIV infections per 1000 person-years (95 percent
confidence interval, 1.8 to 2.6). The measured in-
cidence was higher among blacks (3.0 infections
per 1000 person-years; 95 percent confidence in-
terval, 2.4 to 3.8) than among whites (1.6 infections
per 1000 person-years; 95 percent confidence in-
terval, 1.0 to 2.1) and higher among persons old-
er than 24 years (3.0 infections per 1000 person-
years; 95 percent confidence interval, 2.4 to 3.7)
than among those 24 years of age or younger (1.3
infections per 1000 person-years; 95 percent con-
fidence interval, 0.9 to 1.8). A higher estimated in-
cidence of HIV among men (4.3 infections per 1000
person-years; 95 percent confidence interval, 3.3
to 5.2) than among women (1.2 infections per 1000
person-years; 95 percent confidence interval, 0.8
to 1.6) was driven by the much higher incidence
rate among the small number of men who report-
ed having sex with men (21.4 infections per 1000
person-years; 95 percent confidence interval, 15.6
to 28.8).
costs
Costs associated with nucleic acid amplification
testing required a $402,861 (3.3 percent) increase
over the annual budget of $12,053,465 dedicated
to other HIV-related services — education, counsel-
ing, testing, field services, and surveillance activi-
ties (summarized in Fig. 1) — for the same year. Six-
ty-three percent of the additional costs ($251,900)
went to specimen pooling and supplies used in
nucleic acid amplification testing, including capital
equipment costs; the remaining funds supported
the shipment of specimens, technologists’ time, ad-
ministration, reporting of results, and management
of data. The total expenditure for nucleic acid am-
plification testing reflected an added cost of $3.63
per processed specimen and $17,515 per addition-
al diagnosed index case of HIV infection. This cost-
effectiveness reflected the use of one nucleic acid
amplification test per approximately 80 specimens
submitted.
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In this study, we found that antibody tests alone de-
tected only 96 percent of HIV infections, as com-
pared with an algorithm that included nucleic acid
amplification tests to detect acute HIV infections.
There are three principal reasons why the detection
of such infections is especially important. First, the
recognition of acute HIV infection allows appropri-
ate clinical management. For the infected person, a
prompt diagnosis can prevent the administration
of inappropriate tests and therapies often used to
evaluate and treat the symptoms of acute retroviral
infection.24 When indicated, antiretroviral therapy
can be provided. The hypothesis that even short-
term antiretroviral therapy that is initiated in pa-
tients with acute HIV infection may delay the pro-
gression of disease25 is currently being evaluated in
clinical trials.
Second, the identification of persons with acute
HIV infection can help prevent further transmis-
sion of the virus. The probability of transmission is
high during the first few months after acute HIV in-
fection,1-5,26 during which time patients have a high
viral burden in the blood and genital tract1 and are
likely to engage in risky sexual behavior.27 Stan-
dard voluntary counseling and testing practices for
HIV identify many patients as HIV-positive with ad-
vanced disease,28,29 after most sexual transmis-
sion is likely to have occurred already.3 The present
study demonstrated that notification of results, ac-
cess to antiretroviral therapy, and partner counsel-
ing and referral services can be instituted for acute-
ly infected persons within days after testing.
Third, the identification of acute infections can
improve HIV surveillance. Standard antibody tests
limit surveillance to the monitoring of populations
living with latent or advanced HIV disease. Since
1998, the CDC has attempted to develop tests to
distinguish recent from established antibody-posi-
tive HIV infections. To date, antibody-based assays
that are used to determine incidence have not
proved accurate enough to guide clinical manage-
ment or epidemiologic investigation,20 and these
tests miss all acute infections. The most widely used
of these antibody assays is now the CDC’s sensi-
tive–less-sensitive enzyme immunoassay, which
demonstrates reduced antibody titers among pa-
tients within 170 days after seroconversion.16,17
This test allows efficient estimation of HIV-infec-
tion incidence rates from cross-sectional sampling
of populations, as described above.16-18 For pas-
sive surveillance based on clinical testing, estimates
of incidence are most appropriately used to moni-
tor trends in incidence prospectively within testing
populations defined by demographic factors or risk
factors.18,20,30 In this study, we demonstrated that
nucleic acid amplification testing and the sensitive–
less-sensitive assay were complementary. In our
patient population, the addition of nucleic acid am-
plification testing increased the number of detected
incident cases by 21 percent over sensitive–less-
sensitive enzyme immunoassay testing alone, there-
by increasing the precision of estimates of incident
cases for ongoing monitoring, without adding mis-
classification error. These findings demonstrate the
potential of nucleic acid amplification testing to in-
crease the accuracy and precision of data for both
passive and active surveillance of HIV incidence.
The identification of acute cases also created the
opportunity for public health officials to investigate
HIV-transmission events systematically. Data from
these investigations provided new details about the
populations that were acquiring and transmitting
HIV in North Carolina. The early detection of an
ongoing outbreak of HIV infection across the state
among young black men who have sex with men23
exemplified the sensitivity of this approach in the
identification of epidemiologic trends and hidden
populations at risk for HIV infection.
This study had several additional, unexpected
findings. More than two thirds of the acute cases
were detected among the one third of the study par-
ticipants who were tested at sexually transmitted dis-
ease clinics. This indicates that the use of nucleic
acid amplification testing in sexually transmitted
disease clinics can readily identify persons with both
acute HIV infection and acute cases of other sexually
transmitted diseases, possibly representing cotrans-
mission of HIV and classic sexually transmitted
pathogens. This dually infected population may be
very likely to transmit HIV as a result of extreme HIV
shedding in genital secretions.1,31 We also noted
that only 30 percent of patients had symptoms of
acute retroviral infection at the time they tested pos-
itive on nucleic acid amplification, indicating that
limitation of this type of testing to patients with
symptoms would be counterproductive.
Finally, we noted that an automated, high-
throughput approach to specimen pooling result-
ed in excellent performance and cost-effectiveness
with nucleic acid amplification tests. The total add-
ed testing cost of $3.63 per specimen (inclusive of
all costs for equipment, kits, labor, and adminis-
discussion
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tration) increased the overall costs of HIV testing
and surveillance in North Carolina by only about
3 percent. Costs were lower than would be expected
for any alternative methods used to diagnose acute
HIV infection, including individual nucleic acid am-
plification tests, p24-antigen tests, or fourth-gener-
ation antigen–antibody enzyme immunoassay tests.
Formal cost-effectiveness studies of nucleic acid am-
plification testing should be conducted. We noted
substantial variation in the recognition of acute HIV
infection among the types of testing sites and the
categories of risk and demographic characteristics
in this study; additional studies are needed to ex-
plore whether such criteria might help guide the use
of supplemental nucleic acid amplification testing.
The inclusion of all state-funded testing per-
formed during an entire year ensured that the
present study would accurately reflect testing per-
formance in public health practice. The generaliz-
ability of our findings to other states or to private
medical-practice settings is less clear, although oth-
er preliminary data strongly suggest that many other
testing populations (e.g., persons presenting at ur-
gent care and emergency departments or at high-
risk clinics)9-13 are expected to harbor a greater
number and proportion of acute HIV infections
that are missed by current antibody testing than
North Carolina’s general testing population. We be-
lieve that the work that has been done to date with
nucleic acid amplification testing for HIV is now
sufficient to allow us to conclude that this form of
testing should be a standard tool for the prevention
and surveillance of HIV infection and for the care of
infected persons.
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